Filtered By:
Procedure: Transplants
Countries: Canada Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

When does life end? New organ donation strategy fuels debate
On a chilly holiday Monday in January 2020, a medical milestone passed largely unnoticed. In a New York City operating room, surgeons gently removed the heart from a 43-year-old man who had died and shuttled it steps away to a patient in desperate need of a new one. More than 3500 people in the United States receive a new heart each year. But this case was different—the first of its kind in the country. “It took us 6 months to prepare,” says Nader Moazami, surgical head of heart transplantation at New York University (NYU) Langone Health, where the operation took place. The run-up included oversight from an ethi...
Source: ScienceNOW - May 11, 2023 Category: Science Source Type: news

A brain-based definition of death and criteria for its determination after arrest of circulation or neurologic function in Canada: a 2023 clinical practice guideline
Can J Anaesth. 2023 May 2. doi: 10.1007/s12630-023-02431-4. Online ahead of print.ABSTRACTThis 2023 Clinical Practice Guideline provides the biomedical definition of death based on permanent cessation of brain function that applies to all persons, as well as recommendations for death determination by circulatory criteria for potential organ donors and death determination by neurologic criteria for all mechanically ventilated patients regardless of organ donation potential. This Guideline is endorsed by the Canadian Critical Care Society, the Canadian Medical Association, the Canadian Association of Critical Care Nurses, Ca...
Source: Canadian Journal of Anaesthesia - May 2, 2023 Category: Anesthesiology Authors: Sam D Shemie Lindsay C Wilson Laura Hornby John Basmaji Andrew J Baker C écile M Bensimon Jennifer A Chandler Micha ël Chassé Rosanne Dawson Sonny Dhanani Owen T Mooney Aimee J Sarti Christy Simpson Jeanne Teitelbaum Sylvia Torrance J Gordon Boyd Joann Source Type: research

Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association.
c Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research Abstract Cannabis, or marijuana, has potential therapeutic and medicinal properties related to multiple compounds, particularly Δ-9-tetrahydrocannabinol and cannabidiol. Over the past 25 years, attitudes toward cannabis have evolved rapidly, with expanding legalization of medical and recreational use at the state level in the United States and recreational use nationally in Canada and Uruguay. As a res...
Source: Circulation - August 4, 2020 Category: Cardiology Authors: Page RL, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, Piano MR, Rana JS, Saucedo JF, American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Bas Tags: Circulation Source Type: research

Status, Indications, and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review
In conclusion, the Syncardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomic conditions.RésuméLes auteurs décrivent l’utilisation, les indications et les résultats actuels du cœur artificiel total (CAT) temporaire Syncardia (Syncardia Systems, Tucson, AZ, États-Unis), le seul CAT actuellement approuvé comme stratégie de transition vers une transplantation au Canada, aux États-Unis et en Europe. Implanté chez plus de 1 700 patients dans le monde, le CAT temporaire Syncardia est la pompe la plus utilisée. À l’échelle mondia...
Source: Canadian Journal of Cardiology - February 7, 2020 Category: Cardiology Source Type: research

Status, Indications and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review
In conclusion, the SynCardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomical conditions.
Source: Canadian Journal of Cardiology - November 30, 2019 Category: Cardiology Source Type: research

Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation.
CONCLUSIONS LV geometric parameters beyond LVH alone can assist post-transplant prognostication in kidney transplant candidates. PMID: 30787265 [PubMed - in process]
Source: Annals of Transplantation - February 21, 2019 Category: Transplant Surgery Authors: Malyala R, Rapi L, Nash MM, Prasad GVR Tags: Ann Transplant Source Type: research

Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation
ConclusionsPatients with CS have similar post-transplant hemodynamics as patients without CS, without evidence of right ventricular dysfunction or pulmonary hypertension. Neither significant rejection nor recurrence of sarcoid in the allograft was observed in this cohort of patients with CS. Survival is similar between patients with CS and those without CS. Heart transplant is a viable strategy in selected patients with CS with excellent outcomes.RésuméIntroductionLa transplantation cardiaque orthotopique (TCO) est de plus en plus utilisée lors d’insuffisance cardiaque terminale liée à une sarcoïdose cardiaque (SC)...
Source: Canadian Journal of Cardiology - July 24, 2018 Category: Cardiology Source Type: research

Medtronic ’s HVAD System Just Became Less Invasive
Medtronic has gained FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for advanced heart failure patients. The Dublin-based company picked up the technology when it acquired HeartWare in 2016. The firm said the technology is the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest. FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for ...
Source: MDDI - July 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Cardiac output-based fluid optimization for kidney transplant recipients: a proof-of-concept trial
ConclusionsGoal-directed fluid therapy did not alter the volume of fluid administered or the incidence of complications. This proof-of-concept trial provides needed data for conducting a larger trial to determine the influence of fluid therapy on the incidence in DGF in deceased donor kidney transplantation.Trial registrationwww.clinicaltrials.gov (NCT02512731). Registered 31 July 2015.
Source: Canadian Journal of Anesthesia - July 11, 2018 Category: Anesthesiology Source Type: research

A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research

Cardiac output-based fluid optimization for kidney transplant recipients: a proof-of-concept trial.
CONCLUSIONS: Goal-directed fluid therapy did not alter the volume of fluid administered or the incidence of complications. This proof-of-concept trial provides needed data for conducting a larger trial to determine the influence of fluid therapy on the incidence in DGF in deceased donor kidney transplantation. TRIAL REGISTRATION: www.clinicaltrials.gov (NCT02512731). Registered 31 July 2015. PMID: 29637407 [PubMed - as supplied by publisher]
Source: Canadian Journal of Anaesthesia - April 10, 2018 Category: Anesthesiology Authors: Corbella D, Toppin PJ, Ghanekar A, Ayach N, Schiff J, Van Rensburg A, McCluskey SA Tags: Can J Anaesth Source Type: research

Invasive Hemodynamics and Rejection Rates in Patients with Cardiac Sarcoidosis After Heart Transplantation
Conclusions CS patients have similar post-transplant hemodynamics as non-CS patients, without evidence of RV dysfunction or pulmonary hypertension. No significant rejection nor recurrence of sarcoid in the allograft were observed in this cohort of patients with CS. Survival is similar between CS and non-CS patients. Heart transplant is a viable strategy in selected CS patients with excellent outcomes. Teaser Orthotopic heart transplant (OHT) is utilized for end-stage heart failure due to cardiac sarcoidosis (CS). There is a lack of data on long-term outcomes. We explored changes in hemodynamics, allograft rejection and sur...
Source: Canadian Journal of Cardiology - April 7, 2018 Category: Cardiology Source Type: research